Skip to content
Inciteful Med

Diagnosing ARSACS: Understanding Genetics, MRI, and Eye Exams

Published: | Updated:

ARSACS is diagnosed using a combination of brain MRIs showing unique 'pontine stripes', OCT eye exams revealing thickened retinal nerve fibers, and genetic tests identifying mutations in the SACS gene. These specific hallmarks help doctors distinguish ARSACS from other neurological disorders.

Key Takeaways

  • • Brain MRIs in ARSACS often show unique structural changes, including cerebellar vermis atrophy and pontine stripes.
  • • An OCT eye exam typically reveals a thickened retinal nerve fiber layer (RNFL), which is considered a definitive hallmark of the disease.
  • • A confirmed diagnosis requires genetic testing to identify two mutations (biallelic) in the SACS gene.
  • • Electromyography (EMG) and nerve conduction studies are used to document the extent of sensorimotor neuropathy in the arms and legs.

Navigating the diagnostic process for ARSACS often feels like learning a new language. You may find yourself staring at complex medical reports filled with terms like “vermis atrophy” or “biallelic mutations.” Understanding these hallmarks is empowering—it allows you to audit your own care, ask better questions, and confirm that your medical team is looking at the right indicators.

The MRI: Finding the “Stripes”

A Brain MRI (Magnetic Resonance Imaging) uses strong magnets to create detailed pictures of the brain. In ARSACS, doctors look for very specific structural changes that act like a “fingerprint” for the disease [1][2].

  • Cerebellar Vermis Atrophy: The cerebellum is the part of the brain responsible for balance. The vermis is the central strip of the cerebellum. In ARSACS, this area often shows atrophy (shrinking), particularly in the upper (superior) section [3][1].
  • Pontine Stripes: This is one of the most unique signs of ARSACS. On certain MRI views (T2-weighted), doctors may see dark, linear marks in the pons (part of the brainstem). These are often called “pontine stripes” [2][1].
  • Bithalamic Stripes: Similar to the pontine stripes, some patients show bright rims or lines around the thalami (the brain’s relay centers), which further helps distinguish ARSACS from other similar conditions [1][4].

The Eye Exam: A Unique Discovery

One of the most powerful tools for diagnosing ARSACS isn’t a brain scan, but an eye test called Optical Coherence Tomography (OCT). This is a quick, painless scan of the back of the eye [5].

In almost all other similar neurological diseases, the Retinal Nerve Fiber Layer (RNFL)—the layer of nerve fibers in the retina—becomes thinner over time. In ARSACS, the RNFL is characteristically thickened [5][6]. This finding is so specific to ARSACS that many specialists consider it a definitive hallmark of the disease [7][8]. This thickening is likely due to tissue overgrowth (hypertrophy) that occurs early in development [9].

Genetics: Confirming the SACS Mutation

While scans provide clues, genetic testing provides the “final word.” ARSACS is caused by mutations in the SACS gene [10].

  • Biallelic Mutations: Because ARSACS is a recessive condition, you must have two mutations in the SACS gene—one from each parent [11][12]. This is called a “biallelic” mutation.
  • Homozygous vs. Compound Heterozygous: If both mutations are exactly the same, it is called homozygous. If they are two different types of mutations in the same gene, it is called compound heterozygous [11][13].
  • Testing Methods: Doctors may use a “multigene panel” (which looks at a specific group of ataxia-related genes) or Whole Exome Sequencing (WES), which scans almost all of your genes to find rare or novel mutations [14][15].
  • Genetic Counseling: A Genetic Counselor is an essential resource here. They can help you understand the implications of these results for your wider family, such as whether your siblings should be tested or what the risks are for your future children [10].

EMG and Nerve Conduction Studies

In addition to scans, doctors often use Electromyography (EMG) and Nerve Conduction Studies (NCS) to evaluate the health of your muscles and the peripheral nerves that control them. These tests measure electrical activity and how fast nerves send signals, helping doctors confirm the presence of sensorimotor neuropathy (nerve damage in the arms and legs) [16].

Completeness Checklist

When reviewing your medical records, check for these key elements to ensure a comprehensive diagnosis:

Test What to Look For Significance
Brain MRI “Superior vermis atrophy” or “Pontine hypointensities” [1] Confirms structural brain changes consistent with ARSACS.
OCT Scan “Increased peripapillary RNFL thickness” [5] A highly specific “hallmark” that separates ARSACS from other ataxias.
Genetic Report “Biallelic SACS variants” (Pathogenic or Likely Pathogenic) [10] The definitive biological confirmation of the disease.
EMG/NCS “Axonal” or “Demyelinating” sensorimotor neuropathy [16] Documents the extent of nerve involvement in the limbs.

If these terms are missing or unclear in your reports, it is a perfect opportunity to ask your neurologist for more detail. After diagnosis, your next step is understanding the future and Progression and What to Expect.

Frequently Asked Questions

What does an OCT eye exam show in an ARSACS diagnosis?
An OCT scan is a painless eye test that measures the retinal nerve fiber layer. In ARSACS, this layer is characteristically thickened, which is a highly specific hallmark that helps distinguish it from other similar conditions.
What are pontine stripes on an MRI report?
Pontine stripes are dark, linear marks seen in the brainstem on certain types of MRI scans. These stripes act as a unique structural fingerprint that helps doctors identify ARSACS.
What does a biallelic SACS mutation mean?
A biallelic mutation means you have inherited two altered copies of the SACS gene, one from each parent. When genetic testing shows these mutations are pathogenic, it provides definitive biological confirmation of ARSACS.
Why do doctors order an EMG test for ARSACS?
Doctors use an EMG and nerve conduction studies to measure electrical activity in your muscles and peripheral nerves. This helps identify sensorimotor neuropathy, which is the specific nerve damage in the arms and legs associated with ARSACS.
What is cerebellar vermis atrophy?
The cerebellar vermis is the central strip of the cerebellum, the part of the brain responsible for balance. Atrophy means this area has started to shrink, which is a common finding on the brain MRI of someone with ARSACS.

Questions for Your Doctor

  • • Does the MRI report mention 'pontine stripes' or 'bithalamic stripes', and what do these mean for my diagnosis?
  • • Can you confirm if the OCT scan showed 'RNFL thickening' specifically, rather than thinning?
  • • Are the SACS gene mutations identified as 'pathogenic' or 'likely pathogenic', and are they 'homozygous' or 'compound heterozygous'?
  • • How do the 'neurogenic changes' on the EMG correlate with the muscle weakness I am experiencing?
  • • Do the MRI findings show 'supratentorial' changes, and should we be monitoring for any cognitive or emotional shifts?

Questions for You

  • • Do you have copies of your MRI, OCT, and genetic test reports in a single folder or digital file?
  • • When looking at your test results, are there specific medical terms that haven't been explained to you yet?
  • • Have you noticed any changes in your vision, even if they seem minor, that you should share with your ophthalmologist?
  • • Does knowing that these tests show specific 'hallmarks' of ARSACS help you feel more confident in the diagnosis?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    Clinical and Molecular Findings of Autosomal Recessive Spastic Ataxia of Charlevoix Saguenay: an Iranian Case Series Expanding the Genetic and Neuroimaging Spectra.

    Ashrafi MR, Mohammadi P, Tavasoli AR, et al.

    Cerebellum (London, England) 2023; (22(4)):640-650 doi:10.1007/s12311-022-01430-3.

    PMID: 35731353
  2. 2

    ARSACS as a Worldwide Disease: Novel SACS Mutations Identified in a Consanguineous Family from the Remote Tribal Jammu and Kashmir Region in India.

    Kuchay RAH, Mir YR, Zeng X, et al.

    Cerebellum (London, England) 2019; (18(4)):807-812 doi:10.1007/s12311-019-01028-2.

    PMID: 30963395
  3. 3

    Widening the clinical, radiological and genetic spectrum of autosomal recessive ataxia of Charlevoix-Saguenay in Indian patients.

    Divya KP, Cherian A, Dhing HK, et al.

    Acta neurologica Belgica 2024; (124(2)):475-484 doi:10.1007/s13760-023-02400-0.

    PMID: 37898963
  4. 4

    MRI-ARSACS: An Imaging Index for Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay (ARSACS) Identification Based on the Multicenter PROSPAX Study.

    Scaravilli A, Negroni D, Senatore C, et al.

    Movement disorders : official journal of the Movement Disorder Society 2024; (39(8)):1343-1351 doi:10.1002/mds.29871.

    PMID: 38847051
  5. 5

    Optical coherence tomography in autosomal recessive spastic ataxia of Charlevoix-Saguenay.

    Parkinson MH, Bartmann AP, Clayton LMS, et al.

    Brain : a journal of neurology 2018; (141(4)):989-999 doi:10.1093/brain/awy028.

    PMID: 29538656
  6. 6

    Retinal nerve fiber layer thickening in ARSACS carriers.

    van Lint M, Hoornaert K, Ten Tusscher MPM

    Journal of the neurological sciences 2016; (370()):119-122 doi:10.1016/j.jns.2016.09.023.

    PMID: 27772739
  7. 7

    Absent Foveal Avascular Zone in Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay.

    Douglas VP, Douglas KAA, Miller JB, Gaier ED

    Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society 2021; (41(2)):e166-e168 doi:10.1097/WNO.0000000000001050.

    PMID: 32991389
  8. 8

    Retinal Architecture in Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay (ARSACS): Insights into Disease Pathogenesis and Biomarkers.

    Rezende Filho FM, Bremner F, Pedroso JL, et al.

    Movement disorders : official journal of the Movement Disorder Society 2021; (36(9)):2027-2035 doi:10.1002/mds.28612.

    PMID: 33893680
  9. 9

    Thickened Retinal Nerve Fiber Layer Without Hypermyelination in Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay.

    Suarez MK, Martin TJ, Ong SS

    Journal of vitreoretinal diseases 2024; (8(4)):466-470 doi:10.1177/24741264241251582.

    PMID: 39148574
  10. 10

    Assessment of Sacsin Turnover in Patients With ARSACS: Implications for Molecular Diagnosis and Pathogenesis.

    Longo F, De Ritis D, Miluzio A, et al.

    Neurology 2021; (97(23)):e2315-e2327 doi:10.1212/WNL.0000000000012962.

    PMID: 34649874
  11. 11

    Journey Through Autosomal-Recessive Spastic Ataxia of Charlevoix-Saguenay: Insights From a Case Series of Seven Patients-A Single-Center Study and Review of an Indian Cohort.

    Raval MA, Holla VV, Kamble N, et al.

    Journal of movement disorders 2024; (17(4)):430-435 doi:10.14802/jmd.24154.

    PMID: 39198013
  12. 12

    Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay without Spasticity.

    Aida I, Ozawa T, Fujinaka H, et al.

    Internal medicine (Tokyo, Japan) 2021; (60(24)):3963-3967 doi:10.2169/internalmedicine.7401-21.

    PMID: 34121011
  13. 13

    A Novel Homozygous Frameshift Variant of SACS Gene in the Turkish Siblings With Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay (ARSACS).

    Cokyaman T, Saltik ZA, Turan NE

    International journal of developmental neuroscience : the official journal of the International Society for Developmental Neuroscience 2025; (85(3)):e70023 doi:10.1002/jdn.70023.

    PMID: 40396211
  14. 14

    Novel Variants in MPV17, PRX, GJB1, and SACS Cause Charcot-Marie-Tooth and Spastic Ataxia of Charlevoix-Saguenay Type Diseases.

    Zaman Q, Khan MA, Sahar K, et al.

    Genes 2023; (14(2)) doi:10.3390/genes14020328.

    PMID: 36833258
  15. 15

    Clinical and genetic variability among Bulgarian patients with autosomal recessive spastic ataxia of Charlevoix-Saguenay.

    Chamova T, Ivanova N, Cherninkova S, et al.

    Molecular genetics & genomic medicine 2024; (12(7)):e2483 doi:10.1002/mgg3.2483.

    PMID: 39044368
  16. 16

    ARSACS: Clinical Features, Pathophysiology and iPS-Derived Models.

    Salem IH, Blais M, Zuluaga-Sánchez VM, et al.

    Cerebellum (London, England) 2025; (24(1)):24 doi:10.1007/s12311-024-01777-9.

    PMID: 39753868

This page explains ARSACS diagnostic tests and medical terminology for educational purposes. Always consult your neurologist, genetic counselor, or ophthalmologist to interpret your specific scan results and genetic reports.

Stay up to date

Get notified when new research about Autosomal recessive spastic ataxia of Charlevoix-Saguenay is published.

No spam. Unsubscribe anytime.